• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Valeritas jumps on $25m refi, Q3 prelims

October 2, 2019 By Brad Perriello

Valeritas V-Go device - updatedValeritas (NSDQ:VLRX) said today that cut its debt load by $25 million in a refinancing move and released its third-quarter preliminary results, sending its share price up on Wall Street in early trading.

The terms of refi saw the exchange of $25.0 million in senior debt owned by CR Group and another creditor for new Series B convertible shares, cutting its overall senior secured debt to roughly $17.0 million and saving $8 million in interest payments through March 2022.

“As we continue to see strong momentum in V-Go prescriptions from both our tenured sales representatives and our newly hired sales representatives, we were able to work with our creditors to significantly reduce our long-term debt obligations. The reduction in our long-term debt obligations by nearly 60% and the elimination of any cash interest payments until maturity will result in greater financial flexibility, significant cash savings, and better positions us to continue to drive sales growth across our 75 territories in the U.S.,” president & CEO John Timberlake said in prepared remarks.

Bridgewater, N.J.-based Valeritas also said it expects to post sales of about $8.5 million for the three months ended Sept. 30, up some 30% over Q3 2018, and reiterated its annual sales guidance of $31.0 million to $33.0 million.

“We remain confident in our revenue expectations for 2019 as V-Go prescription rates continue to accelerate. Additionally, we are excited by the prospects of regulatory clearance for use of U-100 Regular Human Insulin (RHI) in V-Go, as well as the results of our pharmacokinetic studies using our h-Patch technology to deliver cannabidiol and apomorphine, which will be presented at several industry conferences,” Timberlake said.

Valeritas also said it plans to file for 510(k) clearance during Q1 2020 from the FDA for its V-Go SIM Bluetooth accessory, “which we expect to launch immediately upon clearance by the FDA.”

VLRX shares were up 6.6% to $1.3752 apiece today in early trading.

Filed Under: Diabetes, Featured, Funding Roundup, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Valeritas Inc.

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS